Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
02 Agosto 2023 - 5:30PM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced that
management will participate in the following investor conferences
in August 2023:
Chardan Virtual Ophthalmology SummitAge-Related
Macular Degeneration and Diabetes-Related Eye Diseases
SeriesFireside Chat (Available on Demand)
BTIG Virtual Biotechnology ConferenceCorporate
Presentation and One-on-One Investor MeetingsAugust 7, 2023 at 2:30
pm (Presentation)
H.C. Wainwright 3rd Annual Ophthalmology Virtual
ConferencePanel Discussion, Corporate Presentation and One-on-One
Investor MeetingsAugust 16, 2023 at 11:00 am ET (Panel)
A link to available live and archived webcasts
may be accessed on the Clearside website under the Investors
section: Events and Presentations.
About Clearside Biomedical,
Inc.
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
patented SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina, or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector. The Company’s lead program, CLS-AX
(axitinib injectable suspension), for the treatment of neovascular
age-related macular degeneration (wet AMD), is in Phase 2b clinical
testing. Clearside developed and gained approval for its first
product, XIPERE® (triamcinolone acetonide injectable suspension)
for suprachoroidal use, which is available in the U.S. through a
commercial partner. Clearside also strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. For more information, please visit
clearsidebio.com.
Source: Clearside Biomedical, Inc.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Clearside Biomedical (NASDAQ:CLSD)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024